Nipah Vaccine Shows Promise: Phase 1 Trial Confirms Safety, Immune Response

A Phase 1 clinical trial published in The Lancet reveals a new Nipah virus vaccine candidate, HeV-sG-V, is safe and effectively triggers an immune response. This marks a significant step towards preventing the deadly Nipah infection, particularly relevant for countries like India with recurrent outbreaks. Researchers advocate for further advanced trials.

• Phase 1 trial of HeV-sG-V vaccine showed strong safety profile.
• Vaccine successfully generated immune response in healthy adults.
• Two doses produced robust and lasting antibody responses.
• Minor side effects, no serious adverse events reported.
• Indian experts hail findings as a critical milestone.
• WHO considers Nipah a high-priority pathogen due to high fatality.

Read the full story on Quick Digest.